Daniela Couto, Ph.D., is a Partner with BioGeneration Ventures (BGV) one of the leading pan-European early-stage venture funds. She joined the fund in 2015.

Daniela served as the managing director of BGV’s portfolio company Staten Biotechnology from 2015 to 2018, where she led and executed on company strategy, including the collaboration with argenX and the partnership and buy-out option with Novo Nordisk.

Previously, Daniela served as CEO at Cell2B, a cell therapy company that she co-founded with IP and technology from Prof. Sangeeta Bhatia's lab at the Broad Institute (MIT) for graft-versus-host disease and other immunological diseases.
Daniela holds an MSc degree (cum laude) in Biomedical Engineering from the University of Minho and a PhD degree (sum cum laude) in BioEngineering from Instituto Superior Técnico (IST-UTL) in collaboration with the Massachusetts Institute of Technology (MIT-Portugal Program). Daniela was at Charles L. Cooney lab during her studies at MIT.